Bendamustine
Title: Bendamustine
CAS Registry Number: 16506-27-7
CAS Name: 5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid
Additional Names: g-[1-methyl-5-[bis(b-chloroethyl)amino]-2-benzimidazolyl]butyric acid
Molecular Formula: C16H21Cl2N3O2
Molecular Weight: 358.26
Percent Composition: C 53.64%, H 5.91%, Cl 19.79%, N 11.73%, O 8.93%
Literature References: Bifunctional alkylating agent. Prepn: W. Ozegowski, D. Krebs, J. Prakt. Chem. 20, 178 (1963); eidem, Zentralbl. Pharm. Pharmakother. Laboratoriumsdiagn. 110, 1013 (1971). Antitumor activity: W. Jungstand et al., ibid. 1021. Capillary GC determn in plasma: H. Weber et al., J. Chromatogr. 525, 459 (1990). Toxicity study: U. Horn et al., Arch. Toxicol. Suppl. 8, 504 (1985). Clinical evaluation in non-Hodgkin's lymphomas: K. Bremer, J. Cancer Res. Clin. Oncol. 128, 603 (2002); in chronic lymphocytic leukemia: T. Lissitchkov et al., ibid. 132, 99 (2006); with prednisone in multiple myeloma: W. Pönisch et al., ibid 205. Review of pharmacology and clinical development: K. Bremer, W. Roth, Tumordiagn. Ther. 17, 1-6 (1996); J. A. Barman Balfour, K. L. Goa, Drugs 61, 631-638 (2001).
 
Derivative Type: Hydrochloride
CAS Registry Number: 3543-75-7
Manufacturers' Codes: IMET-3393; SDX-105
Trademarks: Cytostasan; Ribomustin (Ribosepharm); Treanda (Cephalon)
Molecular Formula: C16H21Cl2N3O2.HCl
Molecular Weight: 394.72
Percent Composition: C 48.69%, H 5.62%, Cl 26.95%, N 10.65%, O 8.11%
Properties: Monohydrate mp 152-156°. Sol in water. LD50 (monohydrate) in mice, rats (mg/kg): 400-500, 200-300 orally; 80, 40 i.v. (Horn).
Melting point: mp 152-156°
Toxicity data: LD50 (monohydrate) in mice, rats (mg/kg): 400-500, 200-300 orally; 80, 40 i.v. (Horn)
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Alkylating Agents; Nitrogen Mustards.

Others monographs:
SinomenineEmorfazonep-PhenylenediamineOxaflozane
Lapyrium ChlorideAflatoxins GVogliboseSodium Tartrate
Pipsyl ChlorideDauricineAlprenololDoramectin
EptazocineZirconium ChloridePhenactropinium ChlorideDimorpholamine
©2016 DrugLead US FDA&EMEA